- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.09. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.09. | SL Science Holding Limited: SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing Gamma delta T Cells Target Chemotherapy-Resistant Glioblastoma | 4 | GlobeNewswire (USA) | ||
| 02.09. | SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company | 1 | GlobeNewswire (USA) | ||
| 27.08. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.08. | SL Science licensor files exosome drug master file with FDA | 3 | Investing.com | ||
| 27.08. | SL Science Holding Limited: SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform | 465 | GlobeNewswire (Europe) | TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular... ► Artikel lesen | |
| 17.07. | SL Science presents glioblastoma treatment data at WCP 2026 | 3 | Investing.com | ||
| 17.07. | SL Science präsentiert Daten zur Glioblastom-Behandlung auf Weltkongress | 1 | Investing.com Deutsch | ||
| SL SCIENCE Aktie jetzt für 0€ handeln | |||||
| 17.07. | SL Science Holding Limited: SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology | 1 | GlobeNewswire (USA) | ||
| 10.07. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.07. | SL Science seeks orphan drug status for brain cancer therapy | 4 | Investing.com | ||
| 10.07. | Hirntumortherapie: SL Science beantragt Orphan-Drug-Status | 3 | Investing.com Deutsch | ||
| 10.07. | SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma | 651 | GlobeNewswire (Europe) | Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative... ► Artikel lesen | |
| 18.06. | SL Science Holding Limited Reports Full Year 2025 Financial Results | 568 | GlobeNewswire (Europe) | Taipei, TAIWAN, June 18, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative... ► Artikel lesen | |
| 18.06. | SL Science Holding Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 15.06. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 11 | SEC Filings | ||
| 12.06. | SL Science Holding Limited: SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market | 1.296 | GlobeNewswire (Europe) | Post-combination company, SL Science Holding Limited, to commence trading on the Nasdaq Stock Market under the ticker symbol "SLBT"Transaction provides strategic capital to advance proprietary Gamma... ► Artikel lesen | |
| 11.06. | SL Science Holding Ltd - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 14.01. | SL Science Holding Limited: SL BIO Ltd. and Horizon Space Acquisition II Corp. Announce Registration Statement Effectiveness and Extraordinary General Meeting Date to Approve Business Combination | 345 | GlobeNewswire (Europe) | TAIPEI, Taiwan & NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SL BIO Ltd. ("SL Bio" or the "Company"), a biomedical company specializing in developing innovative cellular and gene therapies, and Horizon... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMYLYX PHARMACEUTICALS | 27,430 | 0,00 % | Amylyx Pharma Q2 2026 Earnings Call Transcript | ||
| TANGO THERAPEUTICS | 21,830 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| QIAGEN | 40,800 | +0,64 % | Pharma-Aktien starten durch: Merck, Qiagen und Bayer im Höhenflug - KI-Boom und US-Megadeal befeuern Branche | Die Aktien von Pharma- und Biotech-Unternehmen erleben am Dienstag einen starken Aufwärtstrend, angeführt von Merck KGaA. Investoren setzen auf Übernahmespekulationen und den KI-getriebenen Innovationsschub... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,960 | +0,06 % | Novo Nordisk zahlt bis zu 2,6 Milliarden Dollar für Biotech - warum Eli Lilly, GSK und AstraZeneca ebenfalls Milliarden auf neue Technologien setzen | ||
| CG ONCOLOGY | 62,38 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,140 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,265 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| NURIX THERAPEUTICS | 22,730 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia | First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 278,18 | +0,06 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| VERA THERAPEUTICS | 30,260 | +0,03 % | Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,140 | 0,00 % | BMO reiterates Trevi Therapeutics stock rating after rival study fails | ||
| ARRIVENT BIOPHARMA | 16,890 | 0,00 % | BTIG cuts ArriVent BioPharma stock price target on trial results | ||
| DYNE THERAPEUTICS | 15,975 | +0,03 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 26,680 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 108,36 | +0,01 % | Citi raises Kymera Therapeutics stock price target on drug potential |
Das Unternehmen SL SCIENCE HOLDING LIMITED kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,500 Euro und damit -0,66 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SL SCIENCE HOLDING LIMITED finden Sie auf Wallstreet Online.